Vestibular Caloric Stimulation and the Modulation of Pain in Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Vestibular Caloric Stimulation and the Modulation of Pain in Fibromyalgia: An Open Label Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05004194
• Other study ID #: GCO 20-2730
• Status: Completed
• Phase: N/A
• Start date: March 19, 2021
• Est. completion date: July 2, 2021

Study information

• Verified date: August 2021
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The management of chronic pains is challenging and fraught with limitations. Fibromyalgia is a common pain disorder characterized by chronic widespread pains, associated with fatigue and impaired quality of life. Fibromyalgia affects millions of people and is among the most common reasons for consulting with a rheumatologist. The food and drug administration (FDA) approved three medications to treat fibromyalgia, though there are many patients for whom these medications are ineffective, poorly tolerated or cost-prohibitive. Accordingly, there exists a need for novel therapeutics.

The researchers would like to test the therapeutic efficacy of a non-pharmacologic non-interventional bedside technique called vestibular caloric stimulation (VCS). VCS, irrigating the external ear canal with water, is a simple, non-invasive, cost-free procedure with preliminary data suggesting potential for improving pain. VCS is a form of neuromodulation and there are anatomically defined pathways elucidated to help explain how this works. There currently exists limited data on the topic, only case reports and case series. Given a clear need for additional therapeutics in many patients with fibromyalgia, the researchers have elected to conduct this trial.

Description:

This is an open label pilot study testing the potential therapeutic efficacy of vestibulocortical stimulation via cold water calorics in fibromyalgia. The trial will entail 6 weeks of total involvement for each participant including 3 weeks of active participation, with 4 weeks follow up: the irrigation happens at the beginning of week 2, so 4 weeks later is week 6.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 2, 2021
• Est. primary completion date: July 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years old with ability to comprehend and consent to protocol.

• Diagnosis of fibromyalgia by American College of Rheumatology (ACR) criteria (questionnaire).

• At least a 4/10 baseline on the visual analogue pain scale (VAS).

• Stable fibromyalgia medications for at least 4 weeks.

• Owns or has access to a smart phone or computer to complete outcome measures.

Exclusion Criteria:

• Use of opioids

• Otitis externa or media within the past six months.

• Current ear pain with or without other symptoms of otitis externa.

• History of tympanic membrane rupture or surgery.

• Current pregnancy.

• Inability to lay supine for 30 minutes.

• Limited decision making capacity.

• Engaged in litigation, currently or prior, related to FMS.

• Inability to commute to clinic once.

• Primary language not English.

• Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation in the study

• Treatment with the medication meclizine for vertigo

• History of seizures

• Diagnosis of bipolar disorder (treated or untreated)

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Procedure:
• Vestibular Caloric Stimulation
Irrigation of the right external ear canal

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Numeric Rating Scale (NRS)	Change in average diary pain scores assessed by daily report on a 11 point numeric rating scale at 1 week after VCS as compared to baseline. Full scale range from 0-10, higher score indicates more pain.	baseline and 1 week after VCS
Secondary	Acute change in NRS	Acute effect of VCS assessed by acute change in pain scores post VCS 5, 15 and 30 minutes post irrigation compared to baseline. Full scale range from 0-10, higher score indicates more pain.	baseline and 5, 15 and 30 minutes after VCS
Secondary	Percentage of participants with NRS pain scores >= to 30% and 50%	Percentage of patients with change in pain assessed by NRS pain scores > or equal to 30% and 50%.	30 minutes, 24 hours, 1 week, 2 weeks after VCS
Secondary	Patient Global Impression of Change (PGIC)	Full score from 0-7, with higher score indicating more improvement.	at 1 weeks, 2 weeks and 4 weeks after VCS
Secondary	Change in Multidimensional Assessment of Fatigue (MAF)	MAF is a 16 item instrument, full scale from 0-50, with higher score indicating more fatigue.	baseline and at 1, 2 and 4 weeks after VCS
Secondary	Michigan Neuropathy Screening Instrument (MNSI)	15 "yes or no" questions - full score from 0-13, with higher score indicating more neuropathic symptoms.	baseline and at 1, 2 and 4 weeks after VCS
Secondary	Change in Brief Pain Inventory Short Form 36 (BPI SF36)	A 9-item instrument with total score from 0 to 10, with higher score indicating worse outcomes. Will exclude question 2 which is a diagram and question 7 which asks about medications.	baseline and at 24 hours, 1 week, 2 weeks, 4 weeks after VCS
Secondary	Change in Fibromyalgia Impact Questionnaire (FIQ)	Full scale from 0-100, with higher score indicating a greater impact of fibromyalgia syndrome.	baseline and at 1, 2 and 4 weeks after VCS
Secondary	Change in Numeric Rating Scale (NRS) for pain in different regions of the body	Pain measured on a numeric rating scale in different regions of the body: the left upper extremity, right upper extremity, left lower extremity, right lower extremity, front of torso, back of torso, head/neck. Full scale range from 0-10, higher score indicates more pain.	baseline and at 24 hours, 1 week, 2 week, 4 week after VCS
Secondary	VCS Tolerability Survey	A seventeen question tolerability instrument developed specifically for caloric stimulation to assess tolerability by measuring the frequency and intensity of headaches, nausea, and vertigo. the tolerability scale does not have a total score just individual questions re headache nausea vertigo discomfort and grades intensities rated on a 0-10 scale, higher numbers reflecting higher severity of symptoms.	24 hours post VCS
Secondary	Number of participants willing to trial VCS again	Number of participants expressing willingness to trial VCS again	24 hours post VCS
Secondary	Change in Subjective Overall Well Being Scale	Subjective Overall Well Being Scale is a 11 point scale with full scale from 0-10, with higher score reflecting the best possible overall subjective disposition	at baseline and at 30 minutes after VCS, 24 hours, 1 week, 2 week and 4 weeks after VCS relative